In the first half of 2025, the price trend for erythromycin remained relatively stable with minor fluctuations influenced by broader market events rather than changes in the drug’s direct supply chain. Being a generic antibiotic, erythromycin continued to be one of the more affordable prescription options, especially compared to brand-name drugs. Patients with insurance typically saw lower out-of-pocket costs, while those without coverage had to shop around or use discount programs to find the best deals.
Public attention toward prescription drug costs increased sharply following President Trump's May executive order aimed at reducing U.S. drug prices. However, since erythromycin is a generic drug and already among the cheaper antibiotics, the executive order had little immediate impact on its pricing. Most changes in the pharmaceutical sector at that time centered around higher-cost, brand-name medications.